Literature DB >> 2473286

Different effects of endothelin-1 on cAMP- and cGMP-mediated vascular relaxation in human arteries and veins: comparison with norepinephrine.

Z H Yang1, F R Bühler, D Diederich, T F Lüscher.   

Abstract

Endothelin-1 (ET-1) is a new cardiovascular hormone produced by endothelial cells. The vascular effects of the peptide and its interaction with cAMP- and cGMP-dependent relaxation were investigated in human arteries and veins. Internal mammary arteries and veins and saphenous veins were obtained intraoperatively and suspended in organ chambers; isometric tension was recorded. The blood vessels were contracted with ET-1 or norepinephrine and relaxations to prostacyclin or sodium nitroprusside were studied. Mammary veins exhibited an enhanced sensitivity to ET-1 (10(-11) to 3 X 10(-7) M) as compared to the artery and saphenous vein (log shift at ED50: 32- and 79-fold, respectively; p less than 0.005). In saphenous veins maximally contracted with ET-1, relaxations to prostacyclin were blunted as compared to the artery (p less than 0.005; n = 5). Similarly, ET-1 inhibited relaxations to sodium nitroprusside in the vein, but not in the artery. In contrast, venous rings contracted with norepinephrine were more sensitive to sodium nitroprusside than the artery. Thus, the human mammary vein, but not the saphenous vein, is more sensitive to the vasoconstrictor effects of ET-1 when compared to the mammary artery. In veins, ET-1 but not norepinephrine inhibits the vascular effects of prostacyclin and sodium nitroprusside, suggesting a specific interaction of the peptide with cAMP- and cGMP-dependent relaxation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2473286     DOI: 10.1097/00005344-198900135-00032

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  9 in total

1.  Effects of endothelin-1 on vascular permeability in the conscious rat: interactions with platelet-activating factor.

Authors:  J G Filep; M G Sirois; A Rousseau; A Fournier; P Sirois
Journal:  Br J Pharmacol       Date:  1991-12       Impact factor: 8.739

2.  Effect of endothelin and endothelin receptor blockade on capillary permeability in experimental pancreatitis.

Authors:  G Eibl; H G Hotz; J Faulhaber; M Kirchengast; H J Buhr; T Foitzik
Journal:  Gut       Date:  2000-03       Impact factor: 23.059

3.  Differential reactivity of human mammary artery and saphenous vein to prostaglandin E(2) : implication for cardiovascular grafts.

Authors:  N Foudi; L Kotelevets; I Gomez; L Louedec; D Longrois; E Chastre; X Norel
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

4.  Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1.

Authors:  Katherine E Wiley; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

5.  Enhancement by endothelin-1 of microvascular permeability via the activation of ETA receptors.

Authors:  J G Filep; M G Sirois; E Földes-Filep; A Rousseau; G E Plante; A Fournier; M Yano; P Sirois
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

6.  Effects of the ETA/ETB receptor antagonist, bosentan on endothelin-1-induced myocardial ischaemia and oedema in the rat.

Authors:  J G Filep; A Fournier; E Földes-Filep
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

7.  Role for endogenous endothelin in the regulation of plasma volume and albumin escape during endotoxin shock in conscious rats.

Authors:  J G Filep
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

8.  Acute pro-inflammatory actions of endothelin-1 in the guinea-pig lung: involvement of ETA and ETB receptors.

Authors:  J G Filep; A Fournier; E Földes-Filep
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

9.  Characterization of receptors mediating vascular responses to endothelin-1 in the conscious rat.

Authors:  J G Filep; M Clozel; A Fournier; E Földes-Filep
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.